Rhea-AI Summary
Petros Pharmaceuticals (PTPI) reported a Nasdaq delisting process. Nasdaq notified the company on November 3, 2025 that it intends to announce the delisting of Petros’ common stock. Nasdaq will file a Form 25 to deregister the stock under Section 12(b), and the delisting becomes effective ten days after that filing.
The stock was suspended from The Nasdaq Capital Market on May 22, 2025 and has traded on the OTCID Basic Market under “PTPI” since July 1, 2025. Petros states trading on the OTCID will continue without disruption, and the company will remain subject to reporting obligations under Sections 13 and 15(d) of the Exchange Act.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.36%
Tags
FAQ
How many Petros Pharmaceuticals (PTPI) SEC filings are available on StockTitan?
StockTitan tracks 22 SEC filings for Petros Pharmaceuticals (PTPI), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for Petros Pharmaceuticals (PTPI)?
The most recent SEC filing for Petros Pharmaceuticals (PTPI) was filed on November 7, 2025.